{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:00:37Z","timestamp":1789614037720,"version":"build-2803163510"},"reference-count":155,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.molmed.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T03:46:51Z","timestamp":1507780011000},"page":"1047-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders"],"prefix":"10.1016","volume":"23","author":[{"given":"Stephen L.","family":"Pinkosky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter H.E.","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra D.","family":"Lalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2017.09.001_bib0005","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2017.09.001_bib0015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2017.09.001_bib0020","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2017.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2010.01.001","article-title":"The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective","volume":"53","author":"Mendis","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.molmed.2017.09.001_bib0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0065-2571(72)90014-3","article-title":"Synthesis and degradation of the lipogenic enzymes of rat liver","volume":"10","author":"Gibson","year":"1972","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.molmed.2017.09.001_bib0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/cr.2008.61","article-title":"Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase","volume":"18","author":"DeBose-Boyd","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.09.001_bib0060","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/205766a0","article-title":"The molecular physiology of citrate","volume":"205","author":"Srere","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.cell.2014.11.020","article-title":"Acetate dependence of tumors","volume":"159","author":"Comerford","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.09.001_bib0070","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.cell.2014.11.025","article-title":"Acetate is a bioenergetic substrate for human glioblastoma and brain metastases","volume":"159","author":"Mashimo","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.09.001_bib0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2014.12.002","article-title":"Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress","volume":"27","author":"Schug","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2017.09.001_bib0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature22405","article-title":"Acetyl-CoA synthetase regulates histone acetylation and hippocampal memory","volume":"546","author":"Mews","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.09.001_bib0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.molcel.2017.04.026","article-title":"Nucleus-translocated ACSS2 promotes gene transcription for lysosomal biogenesis and autophagy","volume":"66","author":"Li","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2017.09.001_bib0090","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ajcn\/70.5.928","article-title":"De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption","volume":"70","author":"Siler","year":"1999","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.molmed.2017.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2016.09.069","article-title":"ATP-citrate lyase controls a glucose-to-acetate metabolic switch","volume":"17","author":"Zhao","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2017.09.001_bib0100","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.09.001_bib0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cmet.2013.04.021","article-title":"Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance","volume":"18","author":"Beaven","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0110","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0115","doi-asserted-by":"crossref","first-page":"15597","DOI":"10.1073\/pnas.0405238101","article-title":"Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription","volume":"101","author":"Ishii","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.09.001_bib0120","doi-asserted-by":"crossref","first-page":"28721","DOI":"10.1074\/jbc.M601576200","article-title":"ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver","volume":"281","author":"Ma","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cmet.2005.03.001","article-title":"LXRs regulate the balance between fat storage and oxidation","volume":"1","author":"Kalaany","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1074\/jbc.M605023200","article-title":"The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR","volume":"282","author":"Cha","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/sqb.2002.67.491","article-title":"SREBPs: transcriptional mediators of lipid homeostasis","volume":"67","author":"Horton","year":"2002","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0140","doi-asserted-by":"crossref","first-page":"33895","DOI":"10.1074\/jbc.M204681200","article-title":"The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes","volume":"277","author":"Berwick","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1042\/bj2880309","article-title":"Identification of multifunctional ATP-citrate lyase kinase as the alpha-isoform of glycogen synthase kinase-3","volume":"288","author":"Hughes","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0150","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/bi00485a011","article-title":"Sequence of sites on ATP-citrate lyase and phosphatase inhibitor 2 phosphorylated by multifunctional protein kinase (a glycogen synthase kinase 3 like kinase)","volume":"29","author":"Ramakrishna","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2017.09.001_bib0155","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/bi992159y","volume":"39","author":"Potapova","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2017.09.001_bib0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmet.2014.06.004","article-title":"Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation","volume":"20","author":"Lee","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0165","doi-asserted-by":"crossref","first-page":"e11612","DOI":"10.7554\/eLife.11612","article-title":"Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation","volume":"5","author":"Covarrubias","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.molmed.2017.09.001_bib0170","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1074\/mcp.M115.057158","article-title":"Nuclear phosphoproteomic screen uncovers ACLY as mediator of IL-2-induced proliferation of CD4+ T lymphocytes","volume":"15","author":"Osinalde","year":"2016","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.molmed.2017.09.001_bib0175","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molcel.2017.06.008","article-title":"Nuclear acetyl-CoA production by ACLY promotes homologous recombination","volume":"67","author":"Sivanand","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2017.09.001_bib0180","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00011.2008","article-title":"AMPK in health and disease","volume":"89","author":"Steinberg","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2017.09.001_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/BJ20120546","article-title":"AMP-activated protein kinase: new regulation, new roles?","volume":"445","author":"Carling","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0190","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.chembiol.2012.08.019","article-title":"AMP-activated protein kinase: a target for drugs both ancient and modern","volume":"19","author":"Hardie","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0195","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/10409238.2010.488215","article-title":"AMPK inhibition in health and disease","volume":"45","author":"Viollet","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0200","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1172\/JCI58554","article-title":"Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction","volume":"121","author":"Schenk","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0205","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1038\/onc.2010.206","article-title":"Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility","volume":"29","author":"Jeninga","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2017.09.001_bib0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/1947601913484496","article-title":"SIRT1: regulator of p53 deacetylation","volume":"4","author":"Lee","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.molmed.2017.09.001_bib0215","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molmet.2015.09.006","article-title":"High intensity interval training improves liver and adipose tissue insulin sensitivity","volume":"4","author":"Marcinko","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1101\/sqb.2011.76.010769","article-title":"On acetyl-CoA as a gauge of cellular metabolic state","volume":"76","author":"Cai","year":"2011","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0225","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2011.06.050","article-title":"Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival","volume":"146","author":"Yi","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.09.001_bib0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ceb.2015.02.003","article-title":"Acetyl-CoA and the regulation of metabolism: mechanisms and consequences","volume":"33","author":"Shi","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0235","doi-asserted-by":"crossref","first-page":"a000562","DOI":"10.1101\/cshperspect.a000562","article-title":"The nuclear pore complex and nuclear transport","volume":"2","author":"Wente","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0240","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmet.2006.04.013","article-title":"GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha","volume":"3","author":"Lerin","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0245","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/sj.onc.1210604","article-title":"Distinct GCN5\/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation","volume":"26","author":"Nagy","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2017.09.001_bib0250","doi-asserted-by":"crossref","first-page":"17187","DOI":"10.1073\/pnas.0808207105","article-title":"The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}","volume":"105","author":"Coste","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.09.001_bib0255","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2720181","article-title":"The effect of (\u2212)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2","volume":"272","author":"Berkhout","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0260","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2017.09.001_bib0265","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.09.001_bib0270","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0962280210394459","article-title":"Using multiple genetic variants as instrumental variables for modifiable risk factors","volume":"21","author":"Palmer","year":"2012","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0275","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.09.001_bib0280","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2015.06.008","article-title":"IMPROVE-IT and genetics reaffirm the causal role of LDL in cardiovascular disease","volume":"241","author":"Catapano","year":"2015","journal-title":"Atherosclerosis"},{"issue":"Suppl 11","key":"10.1016\/j.molmed.2017.09.001_bib0285","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0735-1097(17)35044-1","article-title":"Genetic target validation for ATP-citrate lyase inhibition","volume":"69","author":"Ference","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0290","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1194\/jlr.R600013-JLR200","article-title":"Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies","volume":"47","author":"Parhofer","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0295","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.09.001_bib0300","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ajcn\/74.6.707","article-title":"No common energy currency: de novo lipogenesis as the road less traveled","volume":"74","author":"Hellerstein","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.molmed.2017.09.001_bib0310","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1152\/ajpendo.2002.282.1.E46","article-title":"Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity","volume":"282","author":"Diraison","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0315","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0320","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ajcn\/77.1.43","article-title":"Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets","volume":"77","author":"Schwarz","year":"2003","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.molmed.2017.09.001_bib0325","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI24930","article-title":"Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease","volume":"115","author":"Tamura","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0330","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI200422422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0340","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2013.02.002","article-title":"Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae","volume":"27","author":"Karlas","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0345","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2010 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0350","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0355","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.09.001_bib0360","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.23861","article-title":"Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity","volume":"52","author":"Sachithanandan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0365","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.molmed.2017.09.001_bib0370","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.bbadis.2014.08.004","article-title":"Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?","volume":"1842","author":"Gruben","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2017.09.001_bib0375","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cmet.2012.03.004","article-title":"The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance","volume":"15","author":"Farese","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0380","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1194\/jlr.R800053-JLR200","article-title":"Hepatic triacylglycerol accumulation and insulin resistance","volume":"50","author":"Nagle","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0385","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0022-2275(20)32065-4","article-title":"Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions","volume":"41","author":"Packard","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0390","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/ijo.2008.164","article-title":"Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women","volume":"32","author":"Magkos","year":"2008","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.molmed.2017.09.001_bib0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1098-3597(05)80065-1","article-title":"The metabolic basis of atherogenic dyslipidemia","volume":"7","author":"Vinik","year":"2005","journal-title":"Clin. Cornerstone"},{"key":"10.1016\/j.molmed.2017.09.001_bib0400","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00129784-200505060-00005","article-title":"Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome","volume":"5","author":"Nesto","year":"2005","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.molmed.2017.09.001_bib0405","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/1874192401105010024","article-title":"Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment","volume":"5","author":"Athyros","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0410","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hep.23784","article-title":"Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0415","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/j.gastro.2007.10.039","article-title":"Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease","volume":"134","author":"Puri","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0420","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0425","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00011-011-0417-3","article-title":"FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes","volume":"61","author":"Miao","year":"2012","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0430","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0435","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0028-1091979","article-title":"Abnormalities of lipid metabolism in nonalcoholic fatty liver disease","volume":"28","author":"Cheung","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.molmed.2017.09.001_bib0440","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trsl.2016.07.005","article-title":"Gut microbiome and liver disease","volume":"179","author":"Betrapally","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0445","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/hep.510290632","article-title":"Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways","volume":"29","author":"Svegliati-Baroni","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0450","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0455","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.29246","article-title":"Acetyl-CoA carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study","volume":"66","author":"Stiede","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0460","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(17)30328-8","article-title":"GS-009 \u2013 Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH","volume":"66","author":"Lawitz","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0465","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","article-title":"DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery","volume":"18","author":"Ahrens","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0470","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1186366","article-title":"Genome-wide evolutionary analysis of eukaryotic DNA methylation","volume":"328","author":"Zemach","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.09.001_bib0475","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1073\/pnas.1002588108","article-title":"Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes","volume":"108","author":"Wu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.09.001_bib0480","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1016\/S0021-9258(17)34693-8","article-title":"Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA","volume":"253","author":"McGarry","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0485","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr\u2212\/\u2212 mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0490","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0192623311422078","article-title":"Gene expression in livers of BALB\/C and C57BL\/6J mice fed a high-fat diet","volume":"40","author":"Nishikawa","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0495","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.22774","article-title":"Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice","volume":"49","author":"Wang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0500","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/JME-08-0025","article-title":"Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome","volume":"41","author":"Aagaard-Tillery","year":"2008","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0505","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1172\/JCI41624","article-title":"Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice","volume":"120","author":"Bricambert","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0510","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1101\/gad.364306","article-title":"Acetylation of Stat1 modulates NF-kappaB activity","volume":"20","author":"Kramer","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.molmed.2017.09.001_bib0515","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1242\/jcs.073783","article-title":"SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310","volume":"123","author":"Rothgiesser","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.molmed.2017.09.001_bib0520","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2017.09.001_bib0525","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0530","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0535","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0540","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0022-2275(20)30035-3","article-title":"Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors","volume":"38","author":"Bisgaier","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0545","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0550","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0555","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0560","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0565","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(12)61626-X","article-title":"ETC-1002 lowers LDL-C and beneficially modulates other cardio-metabolic risk factors in hypercholesterolemic subjects with either normal or elevated triglycerides","volume":"59","author":"Ballantyne","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0570","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1006\/bbrc.1999.0510","article-title":"Human very-long-chain acyl-CoA synthetase: cloning, topography, and relevance to branched-chain fatty acid metabolism","volume":"257","author":"Steinberg","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2017.09.001_bib0575","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/S0021-9258(18)69735-2","article-title":"The citrate cleavage enzyme. I. Distribution and purification","volume":"234","author":"Srere","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0580","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1432-1033.1992.tb16659.x","article-title":"Cloning and expression of a human ATP-citrate lyase cDNA","volume":"204","author":"Elshourbagy","year":"1992","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0585","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0021-9258(19)40033-1","article-title":"Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age","volume":"265","author":"Elshourbagy","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0590","doi-asserted-by":"crossref","first-page":"27418","DOI":"10.1074\/jbc.M109.078667","article-title":"Identification of the citrate-binding site of human ATP-citrate lyase using X-ray crystallography","volume":"285","author":"Sun","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0595","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/bi300611s","article-title":"On the catalytic mechanism of human ATP citrate lyase","volume":"51","author":"Fan","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.molmed.2017.09.001_bib0600","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1432-1033.1991.tb16105.x","article-title":"ATP-citrate lyase from rat liver. Characterisation of the citryl-enzyme complexes","volume":"199","author":"Wells","year":"1991","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0605","doi-asserted-by":"crossref","first-page":"42936","DOI":"10.1074\/jbc.M307228200","article-title":"Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene","volume":"278","author":"Ohashi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0610","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1074\/jbc.M310512200","article-title":"ATP-citrate lyase deficiency in the mouse","volume":"279","author":"Beigneux","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0003-9861(69)90532-3","article-title":"Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase","volume":"135","author":"Watson","year":"1969","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.molmed.2017.09.001_bib0620","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02532136","article-title":"Effect of (\u2212)-hydroxycitrate upon the accumulation of lipid in the rat. I. Lipogenesis","volume":"9","author":"Sullivan","year":"1974","journal-title":"Lipids"},{"key":"10.1016\/j.molmed.2017.09.001_bib0625","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/751658","article-title":"Updates on antiobesity effect of garcinia origin (\u2212)-HCA","volume":"2013","author":"Chuah","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.molmed.2017.09.001_bib0630","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-5793(72)80425-3","article-title":"Stimulation of acetyl-CoA carboxylase by (\u2212)-hydroxycitrate","volume":"27","author":"Hackenschmidt","year":"1972","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2017.09.001_bib0635","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02533638","article-title":"Comparative effects of (\u2212)-hydroxycitrate and (+)-allo-hydroxycitrate on acetyl CoA carboxylase and fatty acid and cholesterol synthesis in vivo","volume":"12","author":"Triscari","year":"1977","journal-title":"Lipids"},{"key":"10.1016\/j.molmed.2017.09.001_bib0640","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1568013033483357","article-title":"ATP-citrate lyase: a potential target for hypolipidemic intervention","volume":"3","author":"Groot","year":"2003","journal-title":"Curr. Med. Chem. Immunol. Endocr. Metab. Agents"},{"key":"10.1016\/j.molmed.2017.09.001_bib0645","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bj3340113","article-title":"The role of ATP citrate-lyase in the metabolic regulation of plasma lipids Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076","volume":"334","author":"Pearce","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0650","first-page":"396","article-title":"Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs","volume":"48","author":"van Vlijmen","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.molmed.2017.09.001_bib0655","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.bmcl.2007.03.017","article-title":"2-Hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors","volume":"17","author":"Li","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.molmed.2017.09.001_bib0660","doi-asserted-by":"crossref","first-page":"32606","DOI":"10.1074\/jbc.M110.157172","article-title":"ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells","volume":"285","author":"Chu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0665","doi-asserted-by":"crossref","first-page":"35657","DOI":"10.1074\/jbc.M707294200","article-title":"A role for ATP-citrate lyase, malic enzyme, and pyruvate\/citrate cycling in glucose-induced insulin secretion","volume":"282","author":"Guay","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2017.09.001_bib0670","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.molmet.2016.07.011","article-title":"Knockdown of ATP citrate lyase in pancreatic beta cells does not inhibit insulin secretion or glucose flux and implicates the acetoacetate pathway in insulin secretion","volume":"5","author":"El Azzouny","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0675","doi-asserted-by":"crossref","first-page":"F423","DOI":"10.1152\/ajprenal.00029.2017","article-title":"ATP-citrate lyase is essential for high glucose-induced histone hyperacetylation and fibrogenic gene up-regulation in mesangial cells","volume":"313","author":"Deb","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0680","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature10986","article-title":"A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism","volume":"484","author":"Herman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.09.001_bib0685","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1172\/JCI119746","article-title":"Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene","volume":"100","author":"Shimano","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2017.09.001_bib0690","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/ncomms2537","article-title":"De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health","volume":"4","author":"Eissing","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2017.09.001_bib0695","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1158\/0008-5472.CAN-08-1235","article-title":"ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer","volume":"68","author":"Migita","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0700","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1055\/s-2003-43500","article-title":"Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer","volume":"35","author":"Turyn","year":"2003","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0705","first-page":"2625","article-title":"Targets of gene amplification and overexpression at 17q in gastric cancer","volume":"62","author":"Varis","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0710","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-3163-6-8","article-title":"Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women","volume":"6","author":"Yancy","year":"2007","journal-title":"J. Carcinog."},{"key":"10.1016\/j.molmed.2017.09.001_bib0715","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2015.03.004","article-title":"Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer","volume":"88","author":"Osugi","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.molmed.2017.09.001_bib0720","first-page":"7855","article-title":"ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma","volume":"8","author":"Qian","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.molmed.2017.09.001_bib0725","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0730","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2017.09.001_bib0735","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-11-4112","article-title":"ATP-citrate lyase: a key player in cancer metabolism","volume":"72","author":"Zaidi","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2017.09.001_bib0740","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.7314\/APJCP.2014.15.17.7097","article-title":"Fatty acid synthesis pathway genetic variants and clinical outcome of non-small cell lung cancer patients after surgery","volume":"15","author":"Jin","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.molmed.2017.09.001_bib0745","doi-asserted-by":"crossref","first-page":"43713","DOI":"10.18632\/oncotarget.9666","article-title":"Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism","volume":"7","author":"Shah","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2017.09.001_bib0750","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy \u2013 European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2017.09.001_bib0755","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2017.09.001_bib0760","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1254\/jphs.08238FP","article-title":"Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats","volume":"109","author":"Itagaki","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2017.09.001_bib0765","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1211\/jpp.57.11.0014","article-title":"Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein","volume":"57","author":"Matzno","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.molmed.2017.09.001_bib0770","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","article-title":"Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy","volume":"466","author":"Osaki","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2017.09.001_bib0775","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cmet.2015.05.006","article-title":"ATP citrate lyase improves mitochondrial function in skeletal muscle","volume":"21","author":"Das","year":"2015","journal-title":"Cell Metab."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491417301600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491417301600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T16:14:38Z","timestamp":1657642478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491417301600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":155,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1471491417301600"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2017.09.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}